Stemline Therapeutics Announces Date Change for the Company’s Presentation at the 35th Annual J.P. Morgan Healthcare Confer...
January 09 2017 - 5:15PM
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan
Bergstein, M.D., Stemline’s CEO, will now present at the 35th
Annual J.P. Morgan Healthcare Conference on Tuesday, January 10,
2017 at 4:30 PM PT (7:30 PM ET) at the Westin St. Francis Hotel in
San Francisco, CA. A live webcast of the presentation can be viewed
on the company's website at www.stemline.com.
About Stemline TherapeuticsStemline
Therapeutics, Inc. is a clinical stage biopharmaceutical company
developing novel oncology therapeutics. Stemline is developing
three clinical stage product candidates, SL-401, SL-801, and
SL-701. SL-401 is a targeted therapy directed to the interleukin-3
receptor (CD123) present on a wide range of malignancies. SL-401 is
being advanced through a pivotal Phase 2 program in patients with
blastic plasmacytoid dendritic cell neoplasm (BPDCN), an indication
for which SL-401 has been granted Breakthrough Therapy Designation
(BTD) by the FDA. SL-401 has demonstrated high overall response
rates (ORR), with multiple complete responses (CRs), in both
first-line and relapsed/refractory patients, and treatment duration
and frequency of bridge to transplant have been trending favorably.
SL-401 is also being advanced through Phase 1/2 trials of patients
with additional malignancies including acute myeloid leukemia (AML)
in remission with minimal residual disease (MRD), high-risk
myeloproliferative neoplasms (MPN), and relapsed/refractory
multiple myeloma (in combination with pomalidomide). SL-801 is a
novel oral small molecule reversible inhibitor of XPO1 that has
demonstrated broad in vivo and in vitro preclinical activity in a
wide array of solid and hematologic malignancies. A Phase 1 trial
with SL-801 is open and enrolling patients with advanced solid
tumors, and a Phase 1 trial in hematologic malignancies is planned.
SL-701 is an immunotherapy designed to activate the immune system
to attack tumors. A Phase 2 trial with SL-701 in adult patients
with second-line glioblastoma multiforme (GBM) is ongoing. For more
information about Stemline Therapeutics, please visit
www.stemline.com.
Forward-Looking StatementsSome of the
statements included in this press release may be forward-looking
statements that involve a number of risks and uncertainties. For
those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. The factors that could cause our
actual results to differ materially include: the success and timing
of our clinical trials and preclinical studies for our product
candidates, including site initiation, internal review board
approval, scientific review committee approval, patient accrual,
safety, tolerability and efficacy data observed, and input from
regulatory authorities; our plans to develop and commercialize our
product candidates; market acceptance of our products;
reimbursement available for our products; our available cash and
investments; our ability to obtain and maintain intellectual
property protection for our product candidates; our ability to
manufacture; the performance of third-party manufacturers, clinical
research organizations, clinical trial sponsors and clinical trial
investigators; and other risk factors identified from time to time
in our reports filed with the Securities and Exchange Commission.
Any forward-looking statements set forth in this press release
speak only as of the date of this press release. We do not intend
to update any of these forward-looking statements to reflect events
or circumstances that occur after the date hereof.
Contact
Investor Relations
Stemline Therapeutics, Inc.
750 Lexington Avenue
Eleventh Floor
New York, NY 10022
Tel: 646-502-2307
Email: investorrelations@stemline.com
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Sep 2023 to Sep 2024